Kids born with congenital heart disease (CHD) often face a frustrating cycle: get a valve, outgrow it, get another surgery, repeat. The FDA just approved a device that could break that cycle. The Autus Size-Adjustable Valve (Edwards Lifesciences) is the first surgically implanted pulmonary valve designed to expand as a child grows — potentially eliminating the need for repeat open-heart surgery.

Here's how it works: the valve is implanted at ~13 mm (toddler-sized) and can be expanded up to 22 mm (adult-sized) using a non-invasive balloon catheter procedure in a cath lab. It's also the first FDA-approved heart valve made with polymeric (ePTFE) leaflets instead of animal-derived tissue, which tends to stiffen and fail over time.

By the Numbers:

• 62 pediatric patients (ages 18 months–16 years) across 12 U.S. sites enrolled in the pivotal trial
• 100% of patients had successful procedures with zero deaths, strokes, or clot-related complications
• 100% of 1-year follow-up patients showed acceptable valve performance with no reinterventions
• 3 patients had valve frame fractures; 2 had reduced leaflet motion — all asymptomatic
• ~40,000 babies born with CHD in the U.S. each year; ~25% have critical CHD requiring surgery in year one

Why it matters: Repeat open-heart surgeries carry serious risks and take a significant toll on children and families. A valve that grows with the patient — and can be adjusted without going back to the OR — could meaningfully improve quality of life and long-term outcomes for thousands of kids. Longer-term studies are ongoing to confirm durability.